Latest News and Press Releases

MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a...

COMMUNIQUÉ DE PRESSE | Paris, France - 3 décembre 2024 Smart Immune, société de biotechnologie en stade clinique, et CELLforCURE by SEQENS, entreprise de développement et de fabrication en...

PRESS RELEASE | Paris, France – December 3, 2024 Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract Development and Manufacturing Organization (CDMO) for...

Apeiron Therapeutics (Apeiron), a precision oncology company leveraging state-of-the-art structural biology and AI-guided molecular modeling for drug disco

Turnstone reports third quarter 2024 financial results and provides recent business highlights

CMO Dr. Harald Haeske to present innovative approaches for combining ADCs with immune checkpoint inhibitors to enhance therapeutic efficacyOBT will also present insights on its target discovery...

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular...

Cancer Focus Fund invested $5.1M in precision peptide radioligand developer Starget for a Phase 1b trial at MD Anderson of its lead theranostic DOTA-PTR-58

Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.

Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...